Merck Serono

Former Merck Serono headquarters in Geneva could host a new Wyss Institute

Friday, December 7, 2012 01:43 PM

A dedicated consortium comprised of the École Polytechnique Fédérale de Lausanne (EPFL), the University of Geneva (UNIGE), Dr. Hansjörg Wyss and the Bertarelli family has developed a project to convert part of the former Merck Serono site in Geneva, Switzerland, into a multi-development facility.

More... »

UAE, Merck Serono, Neopharma form first pharmaceutical production agreement

Wednesday, December 5, 2012 11:35 AM

Merck Serono, a division of Germany-based Merck, and a local manufacturer, Neopharma, have formed the first partnership of its kind to locally produce Merck branded medication in the UAE for distribution across the Middle East.

More... »

Merck Serono, Auxogyn collaborate on Eeva Test

Friday, October 19, 2012 11:01 AM

Merck Serono, the biopharmaceutical division of Merck, and Auxogyn, a company focused on translating scientific discoveries in early embryo development into clinical tools, have entered into a strategic agreement focused on Auxogyn's proprietary Early Embryo Viability Assessment (Eeva) Test.

More... »

Merck Serono: 40% of Geneva staff have job prospects

Tuesday, October 2, 2012 01:50 PM

Merck Serono has provided an update on the redeployment of its Geneva-based staff, 100 days after announcing its decision to close the site. As of Sept. 28, job prospects have been clarified for more than 500 employees, or 40% of Geneva-based employees:

More... »

Merck Serono spin-off Quartz Bio to offer biomarker data analysis

Tuesday, September 4, 2012 12:41 PM

Merck Serono, a division of Merck, has created Quartz Bio, the second spin-off company resulting from its Entrepreneur Partnership Program launched in April. Quartz Bio will offer biomarker data management and exploratory biomarker analysis services to the pharmaceutical industry. Biomarker analysis is a critical step in the drug development process, as it enables the identification of patient profiles most responsive to a given treatment.

More... »

Quintiles to offer jobs to 100 Merck Serono employees affected by cuts

Wednesday, June 27, 2012 10:16 AM

CRO Quintiles has committed to make at least 100 employment offers within the next three months to Merck Serono employees primarily working in global development and medical function in Geneva.

More... »

Merck Serono, Compugen establish new biomarker company Neviah Genomics

Monday, June 25, 2012 02:52 PM

Merck Serono of Darmstadt, Germany, and Compugen, a therapeutic product discovery company of Tel Aviv, Israel, have established a novel start-up company called Neviah Genomics, focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity.

More... »

Merck Serono announces final efficiency program for Switzerland

Wednesday, June 20, 2012 10:03 AM

After a long consultation process, Merck Serono, the biopharmaceutical division of Merck, had made its final plan for restructuring its operations in Switzerland, closing its Geneva and Coinsins sites.

More... »

Dr. Reddy's and Merck Serono collaborate on biosimilars

Wednesday, June 6, 2012 01:07 PM

Dr. Reddy's Laboratories, an integrated global pharmaceutical company, and Merck Serono, a division of Merck, have formed a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs).

More... »

Merck announces Swiss efficiency program, closure of Geneva office

Wednesday, April 25, 2012 10:05 AM

Global pharmaceutical and chemical company Merck Serono has announced efficiency plans for its Swiss operations as part of its comprehensive transformation program—focused on addressing unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization.

More... »